Diplomat Pharmacy - DPLO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.00
+0 (0.00%)
Get New Diplomat Pharmacy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DPLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DPLO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Diplomat Pharmacy in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.00.

This chart shows the closing price for DPLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Diplomat Pharmacy. This rating has held steady since January 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2020Credit Suisse GroupDowngradeNeutral ➝ Underperform$4.00Low
1/8/2020Wells Fargo & CompanyBoost TargetEqual Weight$3.00 ➝ $4.00Low
12/9/2019William BlairUpgradeUnderperform ➝ Market PerformHigh
12/9/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/13/2019BarclaysDowngradeOverweight ➝ Equal Weight$7.00 ➝ $3.00High
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageSell$4.00High
8/13/2019Wells Fargo & CompanyBoost TargetMarket Perform$5.00 ➝ $5.50Low
8/12/2019Wells Fargo & CompanyReiterated RatingHoldLow
8/9/2019BarclaysSet TargetBuy$7.00Low
4/29/2019Credit Suisse GroupLower TargetNeutral ➝ Neutral$8.00 ➝ $6.00Low
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$6.00Medium
4/2/2019Credit Suisse GroupLower TargetNeutral ➝ Neutral$10.00 ➝ $8.00Low
3/21/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$5.86 ➝ $8.00High
3/19/2019Wells Fargo & CompanyLower TargetMarket Perform$16.00 ➝ $6.00High
3/18/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00High
3/18/2019JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$8.00 ➝ $7.00High
3/18/2019MizuhoBoost TargetNeutral ➝ Reduce$6.00 ➝ $8.00High
2/25/2019BarclaysReiterated RatingOverweight ➝ Overweight$18.00 ➝ $8.00Medium
2/25/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00 ➝ $6.00High
2/22/2019MizuhoSet TargetHold$8.00High
2/22/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$9.00 ➝ $8.00Low
2/22/2019William BlairDowngradeMarket Perform ➝ UnderperformHigh
1/8/2019Lake Street CapitalDowngradeBuy ➝ Hold$30.00 ➝ $15.00High
1/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
12/7/2018Robert W. BairdUpgradeUnderperform ➝ Neutral$10.00 ➝ $15.00High
12/3/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $18.00Medium
11/9/2018MizuhoLower TargetNeutral$18.00Medium
11/8/2018Wells Fargo & CompanyLower TargetMarket Perform ➝ Market Perform$23.00 ➝ $16.00High
11/7/2018Robert W. BairdDowngradeNeutral ➝ Underperform$22.00 ➝ $10.00High
7/3/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $21.00Low
6/22/2018SVB LeerinkReiterated RatingOutperform$33.00High
5/10/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
3/8/2018BarclaysInitiated CoverageOverweight ➝ Overweight$27.00Medium
3/2/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyHigh
2/27/2018Needham & Company LLCSet TargetBuy$28.00High
2/27/2018Wells Fargo & CompanyReiterated RatingMarket Perform$21.50 ➝ $25.00High
2/27/2018SVB LeerinkSet TargetOutperform ➝ Buy$32.00 ➝ $30.00High
2/9/2018Lake Street CapitalInitiated CoverageBuy ➝ Buy$35.00High
2/2/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$22.00 ➝ $29.00High
1/25/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$28.00Low
1/24/2018MizuhoSet TargetHold$25.00Low
1/8/2018Needham & Company LLCBoost TargetBuy$24.00 ➝ $26.00Medium
12/11/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$23.00Medium
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$22.00High
11/16/2017Robert W. BairdDowngradeOutperform ➝ Neutral$24.00 ➝ $18.00N/A
11/8/2017Needham & Company LLCBoost TargetBuy$23.75 ➝ $24.00N/A
11/7/2017SVB LeerinkBoost TargetMarket Perform$16.00 ➝ $20.00N/A
11/7/2017MizuhoBoost TargetNeutral ➝ Neutral$16.00 ➝ $20.00N/A
10/24/2017MizuhoSet TargetHold$16.00N/A
10/4/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$19.75 ➝ $23.75N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/7/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/5/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/4/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
10/4/2022

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Diplomat Pharmacy logo
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.
Read More

Today's Range

Now: $4.00
Low: $4.00
High: $4.01

50 Day Range

MA: $4.00
Low: $4.00
High: $4.00

52 Week Range

Now: $4.00
Low: $2.43
High: $14.46

Volume

744,968 shs

Average Volume

545,194 shs

Market Capitalization

$304 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Diplomat Pharmacy?

The following Wall Street research analysts have issued research reports on Diplomat Pharmacy in the last year:
View the latest analyst ratings for DPLO.

What is the current price target for Diplomat Pharmacy?

0 Wall Street analysts have set twelve-month price targets for Diplomat Pharmacy in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Diplomat Pharmacy in the next year.
View the latest price targets for DPLO.

What is the current consensus analyst rating for Diplomat Pharmacy?

Diplomat Pharmacy currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DPLO.

What other companies compete with Diplomat Pharmacy?

Other companies that are similar to Diplomat Pharmacy include Rite Aid, PetMed Express, JOANN, Village Super Market and Lands' End. Learn More about companies similar to Diplomat Pharmacy.

How do I contact Diplomat Pharmacy's investor relations team?

Diplomat Pharmacy's physical mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company's listed phone number is 888-720-4450 and its investor relations email address is [email protected] The official website for Diplomat Pharmacy is www.diplomatpharmacy.com. Learn More about contacing Diplomat Pharmacy investor relations.